Author

P. Gatel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

G. Bossis· 2 shared G. Cartron· 2 shared M. Piechaczyk· 2 shared C. Recher· 1 shared C. Reynes· 1 shared D. Tempe· 1 shared E. Gueret· 1 shared F. Brockly· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Bossis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

R. Paolillo, M. Boulanger, P. Gatel, L. Gabellier, D. Tempe, R. Hallal, M. De Toledo, J. Moreaux, H. Baik, E. Gueret, C. Recher, J.-E. Sarry, G. Cartron, M. Piechaczyk, G. Bossis

This study identifies NOX2 as a marker of poor prognosis and a contributor to chemoresistance in AML, showing its upregulation in drug-resistant cells and association with adverse outcomes.

bioRxiv · Mar 4, 2021Cancer Biology

Ubiquitin and SUMO conjugation as biomarkers of Acute Myeloid Leukemias response to chemotherapies

P. Gatel, F. Brockly, C. Reynes, M. Pastore, Y. Hicheri, G. Cartron, M. Piechaczyk, G. Bossis

This paper identifies ubiquitin and SUMO conjugation biomarkers to predict AML response to chemotherapy and develops an assay to measure them.

bioRxiv · Oct 31, 2019Cancer Biology